Arbutus Biopharma Corp (NASDAQ: ABUS) is 7.03% higher on its value in year-to-date trading and has touched a low of $2.30 and a high of $4.72 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The ABUS stock was last observed hovering at around $3.27 in the last trading session, with the day’s gains setting it 0.23%.
Currently trading at $3.50, the stock is 5.76% and 4.94% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.44 million and changing 7.03% at the moment leaves the stock -2.45% off its SMA200. ABUS registered 40.56% gain for a year compared to 6-month loss of -10.49%. The firm has a 50-day simple moving average (SMA 50) of $3.3352 and a 200-day simple moving average (SMA200) of $3.5881.
The stock witnessed a 3.86% gain in the last 1 month and extending the period to 3 months gives it a 10.06%, and is 6.71% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.00% over the week and 4.98% over the month.
Arbutus Biopharma Corp (ABUS) has around 44 employees, a market worth around $670.18M and $6.17M in sales. Profit margin for the company is -1133.04%. Distance from 52-week low is 52.17% and -25.93% from its 52-week high. The company has generated returns on investments over the last 12 months (-67.88%).
with sales reaching $2.53M over the same period.The EPS is expected to grow by 37.89% this year, but quarterly earnings will post 12.61% year-over-year. Quarterly sales are estimated to grow 20.25% in year-over-year returns.
Arbutus Biopharma Corp (ABUS) Top Institutional Holders
199.0 institutions hold shares in Arbutus Biopharma Corp (ABUS), with institutional investors hold 70.23% of the company’s shares. The shares outstanding are 189.96M, and float is at 148.63M with Short Float at 6.44%. Institutions hold 54.76% of the Float.
The top institutional shareholder in the company is MORGAN STANLEY with over 20.96 million shares valued at $64.77 million. The investor’s holdings represent 11.1466% of the ABUS Shares outstanding. As of 2024-06-30, the second largest holder is WHITEFORT CAPITAL MANAGEMENT, LP with 12.87 million shares valued at $39.76 million to account for 6.8432 of the shares outstanding. The other top investors are BLACKROCK INC. which holds 11.55 million shares representing 6.1434% and valued at over $35.7 million, while TWO SEAS CAPITAL LP holds 4.5584 of the shares totaling 8.57 million with a market value of $26.49 million.
Arbutus Biopharma Corp (ABUS) Insider Activity
#####
Still, SEC filings show that on Mar 13 ’25, Sofia Michael J. (Officer) Proposed Sale 100,000 shares at an average price of $3.38 for $0.34 million. The insider now directly holds shares of Arbutus Biopharma Corp (ABUS).
